Key result
NOACs cut ischemic stroke risk ~30% with fewer major bleeds in elderly AF.
Why the study?
Oral anticoagulation is the most effective treatment to reduce embolic risk in atrial fibrillation, but it is underused in the elderly because both thromboembolic and hemorrhagic risks increase with age.
This review summarizes risk assessment and pharmacological options for stroke prevention in elderly patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference in elderly AF; leaves open confirmation by dedicated RCTs.
The prevalence of atrial fibrillation increases with age, and as a result the risk of stroke and system embolism is increased when compared with younger patients. This is also matched in an increase in the hemorrhagic risk of using oral anticoagulation. For most patients’ oral anticoagulation is the most effective treatment to reduce embolic risk however it is underused in the elderly for fear of hemorrhage. This article discusses the risk assessment tools for clinical decision making and pharmacological options for the prevention of stroke in the elderly and highlights several practical considerations to use of vitamin K antagonists and newer non-vitamin K dependent oral anticoagulants in this growing population of patients. Nigel P Murray1,2* 1Hospital de Carabineros de Chile, Ñuñoa, Santiago, Chile 2Department of Medicine, University Finis Terrae, Providencia, Santiago, Chile Anticoagulation for Chronic Non Valvular Atrial Fibrillation in the Elderly: A Review Citation: Murray NP (2015) Anticoagulation for Chronic Non Valvular Atrial Fibrillation in the Elderly: A Review. J Hematol Blood Transfus Disord 2: 003.
No takes yet. Share an insight, caveat, or question.
Nigel P Murray (2015) conducted a review in Chronic non-valvular atrial fibrillation in the elderly. Oral anticoagulants (Vitamin K antagonists and non-vitamin K dependent oral anticoagulants including dabigatran, rivaroxaban, and apixaban) vs. Warfarin or aspirin was evaluated on Ischemic stroke and major bleeding. Novel non-vitamin K oral anticoagulants reduce the relative risk of ischemic stroke by approximately 30% with fewer significant bleeds in elderly patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: